{
    "nctId": "NCT00363909",
    "briefTitle": "Citalopram in Treating Postmenopausal Women With Hot Flashes",
    "officialTitle": "Phase III Randomized, Double-Blind, Placebo-Controlled Evaluation of Citalopram for the Treatment of Hot Flashes",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 254,
    "primaryOutcomeMeasure": "Difference in average hot flash score from baseline until week 7 of treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Must meet 1 of the following criteria:\n\n  * History of breast cancer\n\n    * No current malignant disease\n  * No history of breast cancer and refused estrogen replacement therapy due to perceived increased risk of breast cancer\n* Bothersome hot flashes, defined as hot flashes \u2265 14 times/week and of sufficient severity to make the patient desire therapeutic intervention\n* Presence of hot flashes \u2265 1 month prior to study entry\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Postmenopausal, as defined by 1 of the following criteria:\n\n  * Absence of a menstrual period in the past 12 months\n  * Bilateral oophorectomy\n  * Absence of a menstrual period in the past 6 months with follicle-stimulating hormone (FSH) level \\> 40 mIU/mL\n* ECOG performance status 0-1\n* Life expectancy \u2265 6 months\n* Willing to provide blood samples during study participation\n* No history of allergic or other adverse reactions to citalopram hydrobromide or other selective serotonin reuptake inhibitors (SSRIs)\n* No documented mania or hypomania\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 4 weeks since prior and no concurrent antineoplastic chemotherapy\n* At least 4 weeks since prior and no concurrent androgens, estrogens, or progestational agents\n* At least 3 months since prior antidepressant use, including Hypericum perforatum (St. John's wort)\n* Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed if on a constant dose for \u2265 4 weeks and continuing medication during study period\n* No other concurrent or planned agents for treating hot flashes (e.g., phenobarbital, megestrol, or clonidine)\n\n  * Stable dose of vitamin E allowed as long as it was started \\> 30 days prior to study entry\n* Concurrent soy allowed\n* Concurrent gabapentin allowed for reasons other than hot flashes if on a constant dose for \u2265 1 month and continuing during study period",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}